189094-76-6

Upstream product

• 74733-27-0 methyl 4-bromomethyl-2-methoxybenzoate 
• 50-85-1 2-hydroxy-p-toluic acid 
• 127-08-2 potassium acetate 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 81245-24-1 methyl 4-methyl-2-methoxybenzoate 

Downstream Products

• 1351169-42-0 methyl 2-(3-{2-[2-(2-{2-[(S)-2-((2S,3R)-3-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-2-hydroxy-4-phenylbutanamido)-4-methylpentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-27-1 2-[3-(2-{2-[2-(2-{(S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanamido}ethoxy)ethoxy]ethoxy}acetamido)propoxy]-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid 
• 1351169-43-1 (S,E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoate 
• 1351169-28-2 (S,E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoic acid 
• 1351169-33-9 C₂₆H₃₂O₄ 
• 1351169-34-0 C₂₅H₃₁BrO₄ 
• 1351169-35-1 (E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-hydroxybenzoate 
• 1351169-36-2 (E)-methyl 2-[3-(tert-butoxycarbonylamino)propoxy]-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-37-3 (E)-methyl 2-(3-aminopropoxy)-4-[3-(3,5-di-tertbutylphenyl)-3-oxoprop-1-enyl]benzoate hydrochloride 
• 55204-14-3 methyl 4-formyl-2-methoxybenzoate 
• 57757-74-1 3-Methoxy-4-(methoxycarbonyl)benzyl Alcohol 

Relevant academic research and scientific papers

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Design, synthesis and biological evaluation of nuclear receptor-degradation inducers

Compounds that regulate the function(s) of nuclear receptors (NRs) are useful for biological studies and as candidate therapeutic agents. Most such compounds are agonists or antagonists. On the other hand, we have developed specific protein degradation in

Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use

Compounds of formula (I): STR1 wherein: R1 is alkyl; R2a, R2b, R2c and R2d are the same or different and each is hydrogen, optionally substituted alkyl, --(C=O)--B1 (wherein B1 i